U.S. Markets open in 9 hrs 2 mins

How Financially Strong Is Anika Therapeutics, Inc. (NASDAQ:ANIK)?

Alexis Guardo

Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize!

Anika Therapeutics, Inc. (NASDAQ:ANIK), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is ANIK will have to follow strict debt obligations which will reduce its financial flexibility. Zero-debt can alleviate some risk associated with the company meeting debt obligations, but this doesn’t automatically mean ANIK has outstanding financial strength. I will take you through a few basic checks to assess the financial health of companies with no debt.

Check out our latest analysis for Anika Therapeutics

Does ANIK’s growth rate justify its decision for financial flexibility over lower cost of capital?

There are well-known benefits of including debt in capital structure, primarily a lower cost of capital. However, the trade-off is debtholders’ higher claim on company assets in the event of liquidation and stringent obligations around capital management. The lack of debt on ANIK’s balance sheet may be because it does not have access to cheap capital, or it may believe this trade-off is not worth it. Choosing financial flexibility over capital returns make sense if ANIK is a high-growth company. ANIK delivered a negative revenue growth of -4.2%. While its negative growth hardly justifies opting for zero-debt, if the decline sustains, it may find it hard to raise debt at an acceptable cost.

NASDAQGS:ANIK Historical Debt February 20th 19

Can ANIK meet its short-term obligations with the cash in hand?

Given zero long-term debt on its balance sheet, Anika Therapeutics has no solvency issues, which is used to describe the company’s ability to meet its long-term obligations. But another important aspect of financial health is liquidity: the company’s ability to meet short-term obligations, including payments to suppliers and employees. Looking at ANIK’s US$9.3m in current liabilities, it appears that the company has been able to meet these commitments with a current assets level of US$196m, leading to a 21.02x current account ratio. Having said that, a ratio above 3x may be considered excessive by some investors, yet this is not usually a major negative for a company.

Next Steps:

As a high-growth company, it may be beneficial for ANIK to have some financial flexibility, hence zero-debt. Since there is also no concerns around ANIK’s liquidity needs, this may be its optimal capital structure for the time being. Going forward, its financial position may change. I admit this is a fairly basic analysis for ANIK’s financial health. Other important fundamentals need to be considered alongside. You should continue to research Anika Therapeutics to get a more holistic view of the stock by looking at:

  1. Future Outlook: What are well-informed industry analysts predicting for ANIK’s future growth? Take a look at our free research report of analyst consensus for ANIK’s outlook.
  2. Valuation: What is ANIK worth today? Is the stock undervalued, even when its growth outlook is factored into its intrinsic value? The intrinsic value infographic in our free research report helps visualize whether ANIK is currently mispriced by the market.
  3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.